Clinical Trials
20 trialsNCT02116530 2025-01-28
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00719173 2024-11-04
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT02939287 2024-10-22
Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan
Rush University Medical Center
Phase 3 Completed
NCT01661335 2021-03-23
Efficacy of Aprepitant (Emend®) in Children
University of Oklahoma
Phase 3 Completed
NCT01636947 2018-09-25
KMEC
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT01534637 2018-08-15
Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT01450826 2018-06-26
Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
Duke University
Phase 2 Completed
NCT00381862 2017-06-12
Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00248547 2017-05-09
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
OHSU Knight Cancer Institute
Phase NA Completed
NCT00092183 2017-05-05
An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT00092196 2017-05-05
Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00600353 2017-03-09
Multi-day Doses in Prevention of Nausea and Emesis
University of Kansas Medical Center
Phase 2 Completed
NCT00293384 2016-03-15
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
Phase NA Completed
NCT00475085 2015-11-10
Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial
University of Rochester
Phase 3 Completed
NCT00954941 2015-06-25
Ondansetron Versus Aprepitant Plus Ondansetron for Emesis
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00651755 2013-07-02
Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
M.D. Anderson Cancer Center
Phase NA Completed
NCT00314743 2013-05-24
Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation
Washington University School of Medicine
Phase EARLY_PHASE1 Completed
NCT00212602 2012-06-14
ONO-7436 Phase II Study in Japan
Ono Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT00169572 2010-05-10
Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy
GlaxoSmithKline
Phase 2 Completed
NCT00415103 2009-09-18
AMENO-2
PETHEMA Foundation
Phase 4 Completed